All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Legend Biotech, Pfizer, and Roche. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View multiple myeloma content recommended for you
On March 5, 2026, the Multiple Myeloma Hub held a virtual symposium, titled Optimizing dosing of BCMA-directed therapies for improved quality of life in multiple myeloma. The symposium was chaired by Rakesh Popat, with presentations from Fredrik Schjesvold and Hang Quach, concluding with a panel discussion featuring patient representative Lynn Williams. The symposium focused on optimizing the dosing of B-cell maturation antigen (BCMA)-directed therapies to balance efficacy and safety, with the aim of supporting healthcare professionals in improving patient outcomes, including quality of life. Explore each session below:
The Multiple Myeloma Hub held a virtual symposium, titled Optimizing dosing of BCMA-directed therapies for improved quality of life in multiple myeloma. During the symposium, Rakesh Popat, University College Hospital, London, UK, delivered a presentation on quality-of-life (QoL) considerations with BCMA-directed therapies in multiple myeloma.
The Multiple Myeloma Hub held a virtual symposium, titled Optimizing dosing of BCMA-directed therapies for improved quality of life in multiple myeloma. During the symposium, Fredrik Schjesvold, Oslo University Hospital, Oslo, NO, provided an overview of BCMA-directed therapies in multiple myeloma.
The Multiple Myeloma Hub held a virtual symposium, titled Optimizing dosing of BCMA-directed therapies for improved quality of life in multiple myeloma. During the symposium, Hang Quach, St Vincent’s Hospital Melbourne and University of Melbourne, AU, delivered a presentation on optimizing dosing strategies for BCMA-directed therapies in multiple myeloma.
On March 5, 2026, the Multiple Myeloma Hub held a virtual symposium, titled Optimizing dosing of BCMA-directed therapies for improved quality of life in multiple myeloma. Rakesh Popat chaired a panel discussion with patient representative Lynn Williams and faculty members, on real-world experience with belantamab mafodotin in multiple myeloma MM.
This independent educational activity was supported by GSK. All content was developed independently by SES in collaboration with the faculty. The funder was allowed no influence on the content of this activity.
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Hang Quach
Rakesh Popat
Fredrik Schjesvold